Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
OBJECTIVE: Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC.
METHODS: Retrospective review was conducted of UPSC from 1982 through 2005. Surgical treatment consisted of hysterectomy, removal of adnexae, and pelvic and paraaortic lymphadenectomy, with or without tumor cytoreduction. Median follow-up was 21 months.
RESULTS: Of the 125 UPSC patients, analysis of stage IIIC-IV patients (n=70; stage IIIC 12, stage IV 58) was performed. Optimal cytoreduction was achieved in 42 of 70 (60%) patients, and optimal cytoreduction with no visible residual disease in 26 of 70 (37%) patients. Patients with no visible residual disease after cytoreduction had a better median survival (51 months) compared to optimally cytoreduced albeit with residual disease (14 months), and suboptimally cytoreduced patients (12 months) (p-value=0.002). Of the 45 patients who received CT, the median survival of patients with no residual disease vs. patients with residual disease was 52 months vs. 16 months (p
DISCUSSION: Cytoreduction to no gross residual disease and the use of CT are associated with a significant survival benefit for patients with stage IIIC-IV UPSC. This effect persisted even in patients who underwent radical resections.
Published In/Presented At
Thomas, M. B., Mariani, A., Cliby, W. A., Keeney, G. L., Podratz, K. C., & Dowdy, S. C. (2007). Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecologic oncology, 107(2), 190–193. https://doi.org/10.1016/j.ygyno.2007.05.039
Medicine and Health Sciences
Department of Obstetrics and Gynecology